Syndromic Surveillance Meaningful Use Recommendations November 16, 2011
Taha A. Kass-Hout, MD, MS Deputy Director for Information Science and BioSense Program Manager Division of Notifiable Diseases and Healthcare Information (DNDHI, Proposed) Public Health Surveillance Program Office (PHSPO) Office of Surveillance, Epidemiology, and Laboratory Services (OSELS) Centers for Disease Control & Prevention (CDC)
Any views or opinions expressed here do not necessarily represent the views of the CDC, HHS, or any other entity of the United States government. Furthermore, the use of any product names, trade names, images, or commercial sources is for identification purposes only, and does not imply endorsement or government sanction by the U.S. Department of Health and Human Services. Office of Surveillance, Epidemiology, and Laboratory Services Public Health Surveillance Program Office
Background
CDC AND ISDS MEANINGFUL USE RECOMMENDATIONS
CMS EHR Incentive Programs “Meaningful Use”
Stage 2 Advanced clinical Stage 1 processes Data capture (2013-2014) and sharing (2011-2012)
Stage 3 Improved outcomes (2015-2016)
Meaningful Use Rules in July 2010
?
?
?
Development Process
THE RECOMMENDATION
CDC and ISDS Recommendation
Responded to needs for
Clarity in the MUse rule for Syndromic Surveillance Support PHA’s participation in MUse Contemporary picture of practice A minimum (core and optional) standard
Is based on Best practices Core business needs
Establishes a foundation
Michael A. Coletta, MPH (Workgroup Chair), Virginia Department of Health Ryan Gentry, Indiana State Department of Health Julia E. Gunn, RN, MPH, Boston Public Health Commission Richard S. Hopkins, MD, MSPH, Florida Department of Health Amy Ising, MSIS, University of North Carolina Department of Emergency Medicine at Chapel Hill Geraldine S. Johnson, MS, New York State Department of Health Bryant T. Karras, MD, State of Washington, Department of Health Karl Soetebier, Georgia Department of Community Health David Swenson, MEd, State of New Hampshire, Department of Public Health Services David Buckeridge, MD, PhD, McGill University and Montreal Public Health Office of Surveillance, Epidemiology, and Laboratory Science and Career Development, CDC Public Health Surveillance Program Office Partnerships and Planning Activity: Pamela A. Meyer, PhD, MSPH Division of Healthcare Information: Samuel Groseclose, DVM, MPH; Taha Kass-Hout, MD, MS Public Health Informatics and Technology Program Office: Standards and Inoperability: Nikolay Lipskiy, MD, DrPH, MBA Northrop Grumman: Sergei Li, PMP; Sundak Ganesan, MD; Mark Meadows; Adam Browning; Mary Hamilton
AHIC Biosurveillance MDS
NHIN Biosurveillance UC
HITSP Biosurveillance Interoperability Specification [20081218 V3.2]
Current SS Landscape •Distribute [40 jurisdictions] •BioSense [28 jurisdictions]
Draft Minimum Data Set
Consensus-driven Development
1. ISDS MU Workgroup informed early iterations. SME’s included representation from CSTE, and NACCHO 2. Stakeholder input help validate, refine and better contextualized the recommendations 3. 41 stakeholders commented; ~ 20% corporations or professional organizations •
4 EP’s or Hospital
•
9 Vendors
•
20 Public Health
•
2 Other
Contents
THE RECOMMENDATION
Scope Data Source: Data on emergency department (ED) and urgent care (UC) patient visits captured by health information system and sent to a public health authority defines the scope of this recommendation. Surveillance Goal: Assessment of community and population health for all-hazards defines the scope of this recommendation. Message and Vocabulary Standards: Standards that support current and continued PHSS improvements, while maintaining consistency with those standards required by the CMS EHR Reimbursement Program define the scope of this recommendation
Meaningful Use Rules in July 2010
?
?
?
Meaningful Use Rules in October 2011 33 Elements 17 Core 16 Optional
3 Core Business Processes Performing Syndrome-based Surveillance
Establishing New Data Source
Monitoring Data Quality
NOW AVAILABLE PHIN Guide for SS : ED & UC Data, Release 1.0
Revised and improved • Based on feedback through Federal Registry post 5/11-6/11 • Better suit the intent of Meaningful Use policy • Added FAQ to address specific issues and needs for clarification
Highlight changes • Data Elements of Interest – Usage • 17 required (R or RE) • 16 optional (O)
• Data Elements of Interest – Vocabulary • Treatment Facility ID • Race, Ethnicity, Gender
• Extended data elements • Increased guidance
• Business rules • Transmission and updating
http://www.cdc.gov/EHRmeaningfuluse/Syndromic.html
Continuing work on PHSS Meaningful Use Develop business and infrastructure requirements for syndromic surveillance using • Inpatient care data • Ambulatory care data (EP’s)
✔
Thank You!
Taha A. Kass-Hout, MD, MS Deputy Director for Information Science and BioSense Program Manager Division of Notifiable Diseases and Healthcare Information (DNDHI, Proposed) Public Health Surveillance Program Office (PHSPO) Office of Surveillance, Epidemiology, and Laboratory Services (OSELS) Centers for Disease Control & Prevention (CDC)
Any views or opinions expressed here do not necessarily represent the views of the CDC, HHS, or any other entity of the United States government. Furthermore, the use of any product names, trade names, images, or commercial sources is for identification purposes only, and does not imply endorsement or government sanction by the U.S. Department of Health and Human Services.
